AI-generated · cited to primary sources · not investment advice · How we research
Neogen Chemicals
Our verdict on Neogen Chemicals isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Ramp battery-chemical sales as US customers shift to non-China/non-FEOC suppliers. — target: Majority of FY27 battery-business revenue in H2, with customer shift expected from January 2027 (+1 more commitment)
“Most of this would be in the second half as the US customers are expecting to shift from China to non-China or FEOC to non-FEOC suppliers from January 2027 onwards.”
Start commercial supplies from the Dahej electrolyte facility by July or August 2026 following customer audits and corrective actions. — target: Commercial supplies to begin by July–August 2026 (+4 more commitments)
“Post audit, they have given us some corrections which we expect to complete within one or two months. And then once we demonstrate that, gradually the commercial supplies can start. So, we expect by July or August 2026, we will have commercial supply start.”
Expand capabilities in adjacent high-end complex chemistries. (+1 more commitment)
“Expand capabilities in adjacent high-end complex chemistries”
Receive Morita's investment for its 20% JV stake. — target: Approximately USD 20 million (+4 more commitments)
“But basically by Q1, we should receive money from there.”
Use backward integration into electrolyte salts, additives and solvent purification to strengthen the battery-materials offering and support customer localization requirements. (+3 more commitments)
“Whatever is the tolling related expenses, that will go away. Of course, some of it will come in the form of additional power and fuel kind of expense at our Dahej plant. But net of what we feel is, you will have improvement in our cost structure.”
See the full cited Management analysis of Neogen Chemicals
How durable is the business?
Inorganic Chemicals was the fastest-growing revenue stream. Q3 revenue rose 35% year on year from INR 24 crore to INR 33 crore, although 9M revenue was down 13% from INR 90 crore to INR 80 crore. The latest-quarter acceleration is the dominant trajectory, and the stream increased its estimated share of Q3 consolidated revenue from approximately 12% to 15%. (5 expanding)
“Inorganic Chemicals: 24 Q3 FY25, 33 Q3 FY26 (+35%); 90 9M FY25, 80 9M FY26 (-13%).”
Battery-chemical scale increased from the previously described Pakhajan plan toward a combined salt capacity of about 5.5 KTA initially, comprising roughly 3 KTA at the greenfield facility and 4 KTA at Dahej for LiPF6-related salt capacity as described by management. Neogen also identified further expansion options: 2 KTA could be added in 9-12 months and another 5 KTA in 15-18 months. The business is therefore moving from planned capacity toward a scalable platform, though commissioning is delayed. (5 expanding)
“The same site which is currently Pakhajan site is starting at a 30 gigawatt hours for salt and electrolyte, but has a room to go up to 100 gigawatt hours. Therefore, the incremental CAPEX would be even more efficient as compared to somebody starting new.”
No updated export percentage was disclosed. International battery demand and customer approvals, however, are progressing: several international customers have approved electrolyte-salt samples, three to four large consumers are actively discussing supply, and customers are moving toward non-FEOC suppliers during 2026 ahead of the 2027 requirement. The export opportunity is therefore expanding in strategic importance, although current revenue share cannot be quantified. (5 expanding)
“Q1 FY27 Revenue break-up**; 70% Domestic; 30% Exports; *Including deemed exports; **Consolidated figures.”
Regulatory positioning strengthened and became more commercially actionable. Previously, Neogen was positioned as a beneficiary of non-China and non-FEOC requirements. In the latest quarter, management reported provisional approvals from multiple global customers, expected audits by Q1 FY27, and strong interest driven by US 45X non-FEOC requirements and Chinese price volatility. This converts a regulatory theme into an emerging order and qualification pipeline. (1 expanding)
“To get this tax credit, a certain value addition or certain percentage of the supply has to be free from supply from foreign entities of concern. So, in such a case, they need to have a non-China kind of a source.”
The customer-qualification moat strengthened. Previously extracted evidence referred to provisional approval from four international customers and audits by four electrolyte manufacturers. In Q2 FY26, Neogen reported that one leading Indian gigafactory had completed PPAP approval for commercial electrolyte supply, while salt had provisional approval pending final improvements. Salt volume agreements covering 5.5 KTA were already in place. This increases commercial qualification and contracted-volume visibility, although final salt approval remains pending. (5 expanding)
“We have secured provisional approvals from 4 international customers for lithium electrolyte salts and successfully completed final site audits from all 4 electrolyte manufacturers.”
See the full cited Business Model analysis of Neogen Chemicals
Where does growth come from?
The earlier Rs. 300 crore FY26 battery revenue expectation has been materially reduced to Rs. 30-40 crore because Indian battery plants and customer approvals were delayed. However, FY27 guidance has shifted to Rs. 400-500 crore, indicating a strong expected acceleration once customers transition suppliers and domestic gigafactories ramp up. (5 accelerating across 5 signals, 3 leading indicators)
“We are looking at INR 300 crore kind of revenue for the current year for the battery business... we have currently approximately kept around INR 200 crore for the salt and INR 100 crore for the electrolyte.”
Battery chemicals are moving from an early-stage business into a large future growth engine. Current FY26 revenue is guided at only Rs. 30-40 crore, but management expects Rs. 400-500 crore in FY27 and Rs. 2,400-2,900 crore at full utilisation by FY29. The opportunity is therefore accelerating, although the near-term ramp has been delayed. (5 accelerating across 5 signals, 1 leading indicator)
“The current CAPEX that is undergoing can cater to give us a revenue of around INR 2,400 crore to INR 2,900 crore depending on the lithium prices ongoing and we expect to achieve this by FY29... Around 40 gigawatt hours of salts and 30 gigawatt hours of electrolyte.”
Reported revenue growth strengthened in the latest quarter: Q4 FY26 revenue was Rs. 247 crore, up 22% year on year, compared with FY26 revenue growth of 11%. The inorganic chemicals segment grew 145% year on year in Q4, while organic chemicals grew 7%. Growth was primarily volume-led, making the latest quarter an acceleration in consolidated revenue momentum. (3 accelerating, 2 new trend across 5 signals)
“Revenue expansion anchored by higher volumes for key product lines; Organolithium Portfolio delivered robust gains driven by enhanced plant throughput; Performance was bolstered by favorable product mix, achieving highest-ever quarterly revenues in both Organolithium and Battery Chemicals, alongside strong volume growth in Inorganic Chemicals.”
The core business has been upgraded to Rs. 950-1,050 crore revenue in FY27, with a possible Rs. 1,100-1,200 crore in FY28 even without major new capacity. Growth should come from Dahej ramp-up, better product selection and larger-volume molecules. — Base business revenue guidance: FY27 guidance raised from Rs. 875-950 crore; FY28 expected growth of 10-15%
“This year’s target we had originally given INR 875 to 950 crore, but based on the Q1 performance, we revised it to INR 950 to INR 1,050 crore... we should be somewhere between INR 1,100 crore to INR 1,200 crore in revenue for the next financial year.”
Export markets remain an important expansion route, with sales spread across the USA, Europe, Middle East, China, Korea and Japan. Exports accounted for 30% of Q1 FY27 sales, and international customer engagement is increasing for battery salts.
“Export sales of 30% in Q1FY27”
See the full cited Future Growth analysis of Neogen Chemicals
What could break the thesis?
Battery sales are concentrated among a small number of large customers and depend on successful qualification by them. Four international customers have approved or audited the facilities, while management is working with five of six large gigafactories; losing or delaying even one major customer could materially affect utilization. [CONCENTRATION] (+1 more risk)
“We have right now worked with 5 out of 6 large gigafactories which are coming and we are very confident that, we should be able to give them an electrolyte which has a similar performance or better as compared to what they are using currently or what has been proposed by their technology partners.”
The Dahej fire shows that a major plant incident can remove capacity, force the company to use toll manufacturers, and create additional rebuilding and operating costs. A repeat incident or problems during restart could again disrupt earnings. [EXECUTION] (+1 more risk)
“Following the fire incident at Dahej plant in March 2025, the current capacity is unavailable. However, a replacement plant of the same capacity is currently under construction, expected to be operational by Q2 FY27”
Exports expose the company to foreign demand, exchange-rate movements, trade restrictions, and shipping disruptions. A large enough global slowdown or freight shock could affect both sales volumes and margins. [CONCENTRATION]
“Export sales of 30% in Q1FY27”
Chinese producers could compete aggressively in bromine, lithium, and battery chemicals, particularly if excess Chinese capacity leads to low-priced exports. This could pressure Neogen's selling prices and delay the expected benefits of the China-plus-one shift. [COMPETITIVE]
“Demand for non-Chinese Electrolyte and Lithium Salts is projected to increase substantially by 2030 ... To secure the US Govt. Tax credit (45X), U.S. LiB cell producers must adhere to Foreign Entity of Concern (FEOC) guidelines”
The competitive risk has eased somewhat from the prior quarter because Chinese prices have firmed and some loss-making producers have shut down. However, Chinese supply remains the benchmark, and customers can still choose imported salt or electrolyte when it is cheaper. The risk therefore remains high rather than resolved. (2 easing, 1 stable)
“Some of these companies were not able to sustain and started closing down. Also, the demand situation is looking better. The overcapacity in China ... is now no longer there ... Therefore, we have seen, firming up of battery material prices, as well as electrolyte, electrolyte salt and to some extent, even cell costs are also likely to go up over the coming year.”
See the full cited Risk analysis of Neogen Chemicals
Read the full thesis on Neogen Chemicals
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.